Oncimmune Holdings PLC
LSE:ONC
Oncimmune Holdings PLC
LSE:ONC
Price:
24 GBX
4.35%
Updated:
May 7, 2024
Oncimmune Holdings PLC
Operating Income
|
Oncimmune Holdings PLC
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Oncimmune Holdings PLC
LSE:ONC
|
Operating Income
-£3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$179.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Oncimmune Holdings PLC's Operating Income?
Operating Income
-3.9m
GBP
-3.9m
GBP
Based on the financial report for Aug 31, 2023, Oncimmune Holdings PLC's Operating Income amounts to -3.9m GBP.
What is Oncimmune Holdings PLC's Operating Income growth rate?
Operating Income CAGR 1Y
38%
38%
Over the last year, the Operating Income growth was 38%.
You don't have any saved screeners yet
